Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BO-112 with radiotherapy and nivolumab in metastatic NSCLC
NCT05265650Phase 2Unknown
- Sponsor
- Universidad de Navarra
- Start
- Jun 2022
- Primary completion
- Mar 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoplexed poly I:C in non-small cell lung cancer (NSCLC), sponsored by Universidad de Navarra. Primary endpoint: Incidence of Adverse events and Serious Adverse Events at 1 year. Status: unknown.
02
Drugs
nanoplexed poly I:C
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05265650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05265650.